Bretylium

Base Information

• Chemical Name: Bretylium
• CAS No.: 59-41-6
• Molecular Formula: C11H17 Br N
• Molecular Weight: 0
• UNII: RZR75EQ2KJ
• DSSTox Substance ID: DTXSID3046958
• Nikkaji Number: J4.602G
• Wikipedia: Bretylium
• Wikidata: Q420026
• NCI Thesaurus Code: C77300
• Pharos Ligand ID: LK4V1U24SZNY
• Metabolomics Workbench ID: 43378
• ChEMBL ID: CHEMBL1199080
• Mol file: 59-41-6.mol

Synonyms:bretylium;bretylium bromide;bretylium chloride;bretylium iodide

Chemical Property of Bretylium

Chemical Property:

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• PSA: 0.00000
• Density: g/cm³
• LogP: 3.04540
• XLogP3: 2.8
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 0
• Rotatable Bond Count: 3
• Exact Mass: 242.05444
• Heavy Atom Count: 13
• Complexity: 156

Purity/Quality:

98%min ^*data from raw suppliers

BRETYLIUM 95.00% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC[N+](C)(C)CC1=CC=CC=C1Br
• Uses: Anti-adrenergic; cardiac depressant (anti-arrhythmic). Bretylium possesses sympatholytic action, which is associated with blockage of norepinephrine (noradrenaline) from presynaptic nerve endings. It also has a direct effect on ischemic myocytes. Bretylium is an urgent treatment that is used in situations of ventricular tachycardia and ventricular fibrillation, primarily in the severe phase of a myocardial infarction, during which use of other medications or procedures have proven unsuccessful. It requires great caution and should be used only in urgent situations.
• Clinical Use: Bretylium (Bretylol) was introduced for the treatment of essential hypertension but subsequently was shown to suppress the ventricular fibrillation often associated with acute myocardial infarction. Bretylium is not to be considered a first-line antiarrhythmic agent. However, because of its ability to prolong the refractory period of Purkinje fibers and to elevate the electrical threshold to ventricular fibrillation, bretylium has been found useful in the treatment of lifethreatening ventricular arrhythmias, especially when conventional therapeutic agents, such as lidocaine or procainamide, prove to be ineffective. In addition, bretylium is known to facilitate the reversal of ventricular fibrillation by precordial electrical shock. Its use should be limited to no longer than 5 days.